HOT NEWS
Novo Nordisk
Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel

Title Filter     Display # 
# Article Title Hits
1 Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A 3345
2 Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia than insulin glargine 3683
3 Novo Nordisk receives positive opinion on recombinant factor XIII 4166
4 43 research talents awarded scholarships to help secure Denmark's future 4634
5 Positive opinion on the use of Levemir® in children with type 1 diabetes aged two to five years 6008
6 Greater overall patient satisfaction when switching from sitagliptin to Victoza® 6495
7 Novo Nordisk to build new corporate centre in Bagsværd, Denmark 5883
8 Novo Nordisk gains EU approval for FlexTouch® 8798
9 Novo Nordisk invests 1 billion Danish kroner in new factory in Denmark 7491
10 New clinical trial data support the use of Levemir® in children aged two to five years 8904
11 Novo Nordisk increased operating profit by 27% in 2010 8038
12 44 research talents get Novo scholarships to write their master theses 7928
13 Novo Nordisk's New Pen for Children - NovoPen Echo(R) - Wins GOOD DESIGN(TM) Award 9262
14 Novo Nordisk's NovoTwist(R) Wins GOOD DESIGN(TM) Award 7977
15 Novo Nordisk A/S and Emisphere Technologies, Inc. Announce Licence Agreement 6053
16 Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial 8151
17 The Lancet publishes new data demonstrating the superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin) 7096
18 Danish companies join forces to compete for global talent 6432
19 Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue 7568
20 Novo Nordisk and Combine in research collaboration for the treatment of autoimmune diseases 4721
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2